Showing 101 - 120 results of 4,647 for search '(( 50 ng decrease ) OR ((( 50 n decrease ) OR ( 50 ((ng decrease) OR (nn decrease)) ))))', query time: 0.67s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104
  5. 105
  6. 106
  7. 107

    Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

    Published 2024
    “…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112

    The impact of excessive DNA amounts used for bisulfite conversion on the amplification efficiency and the methylation level of <i>LINE-1</i> and <i>Alu</i>. by Trang Thi Quynh Tran (20485595)

    Published 2024
    “…A serial dilution of human methylated DNA amounts, corresponding to 500 ng, 50 ng, 5 ng, 1 ng and 0.5 ng was treated by bisulfite. …”
  13. 113
  14. 114
  15. 115

    The GluN2B-C456Y mutation decreases recombinant NMDAR currents and alters receptor properties. by Wangyong Shin (6793040)

    Published 2020
    “…<p>(A) The GluN2B-C456Y mutation strongly decreases diheteromeric GluN1/GluN2B NMDAR currents in <i>Xenopus</i> oocytes. …”
  16. 116

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  17. 117

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  18. 118
  19. 119
  20. 120